Abstract
There have been not many reports on the result of intralesional excision for giant cell tumors (GCTs) of the great trochanter and femoral neck because of its rarity. The authors present the case of a 35-year-old female patient managed with intralesional curettage and filling the defect with autologous bone graft from iliac crest. An appoint of three doses of Denosumab was done postoperatively. The article discusses the clinical aspects and surgical treatment, and the benefits of Denosumab. This report aimed to demonstrate the possibility to perform curetage for giant cell tumor of the hip even the recommandation for this location is wide resection and endoprothesis fixation.
Highlights
Giant cell tumors (GCT) are relatively rare (5% to 10% of bone tumors). They are benign in 90% of cases and more often sit on the limbs (90%) with an almost constant epiphyso-metaphyseal localization: knee (60%), proximal end of the humerus (15%), distal ends of the radius (10%) %) or tibia (10%)
The treatment of the circumscribed giant cell tumors (GCTs) is resolutely surgical and the curettagefilling is the method of choice
The authors state that the patient has freely consented to the publication of the case and that the signed consent is available
Summary
Giant cell tumors (GCT) are relatively rare (5% to 10% of bone tumors). They are benign in 90% of cases and more often sit on the limbs (90%) with an almost constant epiphyso-metaphyseal localization: knee (60%), proximal end of the humerus (15%), distal ends of the radius (10%) %) or tibia (10%). These are tumors of young adults (75% of cases between 20 and 40 years) [1]. There are only a few “case reports” and short series [5] [6] [7] [8], all of which suggest that resection and prosthetic reconstruction is the reference
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
